右佐匹克隆(Eszopiclone) - 药物靶点：GABAA receptor_在研适应症：入睡和睡眠障碍_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate、(+)-(5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl-4-methylpiperazine-1-carboxylate、(+)-Zopiclone

+ [17]

靶点

GABAA receptor

作用机制

GABAA receptor正向变构调节剂(γ-氨基丁酸 A 受体正向别构调节剂)

治疗领域

神经系统疾病

在研适应症

入睡和睡眠障碍

非在研适应症

注意缺陷障碍伴多动重度抑郁症广泛性焦虑障碍+ [3]

原研机构

Sumitomo Pharma America, Inc.

在研机构

Eisai Co., Ltd.

江苏天士力帝益药业有限公司Waylis Therapeutics LLC

非在研机构

Sumitomo Pharma America, Inc.

最高研发阶段批准上市

首次获批日期

美国 (2004-12-15),

入睡和睡眠障碍

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C17H17ClN6O3

InChIKeyGBBSUAFBMRNDJC-INIZCTEOSA-N

CAS号138729-47-2

关联

79

项与右佐匹克隆相关的临床试验

NCT05953610 / Recruiting临床2期IIT

Endotypic Traits and Obstructive Sleep Apnea Surgery

This study will examine factors associated with outcomes after soft palate surgery and medications (acetazolamide, eszopiclone) that may treat other potential causes of obstructive sleep apnea (loop gain, arousal threshold).

开始日期2024-01-07

申办/合作机构

University of California, Los Angeles

[+1]

NCT05951023 / Recruiting临床2期IIT

Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP): a Pilot Trial

More than 10% of the US population have obstructive sleep apnea (OSA). Standard of care is therapy with CPAP (continuous positive airway pressure) which virtually eliminates OSA. However, most patients use CPAP only for part of the night (4-5hours) and about 50% patients discontinue CPAP long-term. Alternative therapies are limited, thus many OSA patients remain at risk of OSA sequelae (e.g. sleepiness, memory issues, high blood pressure, etc.). Importantly, different patients get OSA for different reasons, and recent data show that some of the underlying causes of OSA ("endotypes") such as having a low arousal threshold (i.e. waking up easily) are associated with lower CPAP adherence. Using a randomized controlled trial design, this will be the first study using a targeted intervention to manipulate the underlying OSA causes (i.e., giving a safe hypnotic to patients with OSA to increase the arousal threshold) to test the hypothesis that endotype-targeted therapy increases CPAP-adherence in patients who have low but continued CPAP usage. Ultimately, this strategy may improve the care and outcomes of millions of undertreated OSA patients.

开始日期2023-08-31

申办/合作机构

University of California San Diego

[+1]

NCT06017921 / Recruiting临床4期IIT

Effect of Eszopiclone on Adherence to Continuous Positive Airway Pressure (CPAP) and Severity of Insomnia in Patients With Comorbidity Between Insomnia and Obstructive Sleep Apnea (COMISA)

The comorbidity between obstructive sleep apnea (OSA) and insomnia (COMISA) is common, and associated with poorer sleep quality. CPAP adherence among COMISA patients is worst than among those with OSA only. The investigators will compare the effect of Eszopiclone 3mg or placebo for 14 days on adherence to CPAP after 30 days and after 6 months.

开始日期2023-08-24

申办/合作机构

University of Sao Paulo General Hospital

100 项与右佐匹克隆相关的临床结果

登录后查看更多信息

100 项与右佐匹克隆相关的转化医学

登录后查看更多信息

100 项与右佐匹克隆相关的专利（医药）

登录后查看更多信息

319

项与右佐匹克隆相关的文献（医药）

2024-09-20·CLINICAL NEUROPHARMACOLOGY

Pharmacological Management of Acute and Chronic Insomnia: A Cross-Sectional Study.

Article

作者: Ospina-Sánchez, Santiago ; Sánchez-Ramírez, Nicolás ; Machado-Alba, Jorge Enrique ; Valladales-Restrepo, Luis Fernando ; Usma-Valencia, Andrés Felipe ; Gaviria-Mendoza, Andrés ; Machado-Duque, Manuel

OBJECTIVE:

Insomnia is a frequent and difficult disease to treat. The objective was to determine the pharmacological management of a group of patients diagnosed with acute and chronic insomnia.

METHODS:

This is a cross-sectional study that identified patterns of prescription of drugs for outpatient use in patients with insomnia from a population database of 8.5 million individuals in the Health System of Colombia. Sociodemographic and pharmacological variables were considered.

RESULTS:

A total of 5825 patients with insomnia were identified. Acute insomnia was the most frequent complaint (85.2%). A total of 76.9% received pharmacological treatment, mainly through off-label drugs (70.7%), such as trazodone (20.2%), quetiapine (12.3%), and clonazepam (11.1%). The approved drugs were used in 9.9% of the patients, especially eszopiclone (4.7%) and zopiclone (3.6%). Benzodiazepines and Z compounds predominated in the elderly and individuals with chronic insomnia.

CONCLUSIONS:

The pharmacological treatment of insomnia in this group of patients is heterogeneous, and medications not approved for this indication are very frequently used.

2024-05-03·Expert review of neurotherapeutics

Pharmacological interventions to improve sleep in people with Alzheimer’s disease: a meta-analysis of randomized controlled trials

Review

作者: Donohue, Holly ; Bedward, Amy ; Javed, Amaan ; Hasan, Syed Shahzad ; Seedat, Sadiyah ; Kow, Chia Siang ; Kaur, Jasmine ; Rasheed, Muhammad Kamran

INTRODUCTION:

This systematic review and meta-analysis evaluates the evidence from randomized controlled trials (RCTs) involving pharmacological interventions for improving sleep in people with Alzheimer's disease (AD).

METHODS:

A systematic literature search in eight databases from January 2000 to July 2023 focusing on RCTs that compared a pharmacological intervention with a placebo for enhancing sleep in people with AD. The authors registered the study protocol at Prospero, followed the PRISMA guidelines, and produced the pooled estimates using random-effect or IVhet models.

RESULTS:

Eight different interventions and 29 different sleep outcomes were examined in 14 RCTs included in this review. Eszopiclone positively affected sleep efficiency, as did orexin antagonists. However, there was no difference when melatonin was used. The interventions demonstrated low discontinuation rates and a few adverse drug reactions.

CONCLUSION:

Although melatonin was the most investigated intervention, the evidence for its efficacy is inconclusive. On the other hand, trazodone and orexin receptor antagonists showed promising results; however, more RCTs are needed for definite answers.

2024-04-01·Advances in therapy

Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study

Article

作者: Ohshima, Hayato ; Uchimura, Naohisa ; Hirota, Susumu ; Taninaga, Takehiro ; Murotani, Kenta ; Hayashida, Kenichi ; Habukawa, Mitsunari ; Ariyoshi, Yu ; Harada, Daisuke ; Ozone, Motohiro ; Hiejima, Hiroshi ; Ikegami, Azusa ; Kotorii, Nozomu

INTRODUCTION:

For patients with chronic insomnia, conventional therapy may not always provide satisfactory efficacy and safety. Thus, switching to an alternative therapeutic agent can be explored. However, there is a lack of prospective studies evaluating the effectiveness of such changes. This prospective, non-randomized, open-label, interventional, multicenter study assessed whether Japanese patients with chronic insomnia dissatisfied with treatment could transition directly to lemborexant (LEM) from four cohorts-non-benzodiazepine sedative-hypnotic (zolpidem, zopiclone, or eszopiclone) monotherapy, dual orexin receptor antagonist (suvorexant) monotherapy, suvorexant + benzodiazepine receptor agonists (BZRAs), and melatonin receptor agonist (ramelteon) combination. We evaluated whether transitioning to LEM improved patient satisfaction based on efficacy and safety.

METHODS:

The primary endpoint was the proportion of successful transitions to LEM at 2 weeks (titration phase end), defined as the proportion of patients on LEM by the end of the 2-week titration phase who were willing to continue on LEM during the maintenance phase (Weeks 2-14). Patient satisfaction and safety (the incidence of treatment-emergent adverse events [TEAEs]) were assessed at 14 weeks (end of titration and maintenance phases).

RESULTS:

Among the 90 patients enrolled, 95.6% (95% confidence interval: 89.0-98.8%) successfully transitioned to LEM at 2 weeks. The proportions of patients who successfully continued on LEM were 97.8% and 82.2% at the end of the titration and maintenance phases (Weeks 2 and 14), respectively. The overall incidence of TEAEs was 47.8%; no serious TEAEs occurred. In all cohorts, the proportions of patients with positive responses were higher than the proportions with negative responses on the three scales of the Patient Global Impression-Insomnia version. During the maintenance phase, Insomnia Severity Index scores generally improved at Weeks 2, 6, and 14 of LEM transition.

CONCLUSIONS:

Direct transition to LEM may be a valid treatment option for patients with insomnia who are dissatisfied with current treatment.

TRIAL REGISTRATION:

ClinicalTrials.gov identifier, NCT04742699.

15

项与右佐匹克隆相关的新闻（医药）

2024-08-06

·药通社

重磅新闻！华润斥资62亿，收购天士力！

天士力8月4日下午披露，公司控股股东天士力生物医药产业集团有限公司（下称“天士力集团”）及其一致行动人天津和悦科技等拟向华润三九合计转让其所持有的天士力股份4.18亿股，占公司总股本的28%。与此同时，天士力集团拟向国新投资转让所持有的7469.75万股天士力股份（占比5%）。截至目前，天士力集团及其一致行动人合计持有天士力股票7.54亿元，持股比例为50.5008%。股权转让后，其合计持股下降至2.61亿股，持股比例为17.5008%；华润三九、国新投资的持股比例分别为28%、5%。天士力集团还承诺，股份登记在华润三九名下之日起，其将放弃所持天士力5%股份对应的表决权等，使其控制的表决权比例不超过12.5008%。通过上述交易，华润三九将成为天士力的控股股东，中国华润将成为天士力的实际控制人。并且，据证券时报报道，目前天士力的相关业务与中国华润旗下公司存在同业竞争。华润三九方面承诺，在上述交易完成后五年内解决该同业竞争问题。天士力是A股中药板块龙头之一，产品覆盖中药、化学制剂药、化学原料药、生物药等领域。公司主打产品为复方丹参滴丸等。2023年度，天士力营业收入为86.74亿元，净利润为10.71亿元。今年一季度，公司营业收入为20.49亿元，净利润为2.95亿元。华润三九主要从事医药产品的研发、生产、销售及相关健康服务。公司前身是1985年成立的深圳南方制药厂。1999年，由三九企业集团、深圳三九药业股份有限公司等5家公司发起设立股份制公司。2000年3月9日，公司在深交所上市。2008年，公司正式进入中国华润。华润三九主营核心业务定位于CHC健康消费品和处方药领域。2023年，华润三九拥有年销售额过亿元的品种39个，其中包括“999 感冒灵”“999皮炎平”等。2023年，公司实现营业收入247.39亿元，同比增长36.83%；净利润28.53亿元，同比增长16.50%。 8月4日下午，华润三九也披露了重大资产购买预案。对于收购天士力，华润三九表示，交易有利于公司巩固行业领先地位，提升核心竞争力，通过充分整合双方资源，实现中药产业链的补链强链延链，发挥研发协同价值，符合公司“争做行业头部企业”等企业愿景和发展战略。值得一提的是，天士力的医药零售连锁业务与中国华润下属华润医药的零售连锁业务存在同业竞争，天士力生产的右佐匹克隆片与华润三九生产的佐匹克隆片存在同业竞争。华润三九、中国华润等出具了《关于避免同业竞争的承诺函》，承诺自上述股权交易完成后五年内，按照法定程序通过包括但不限于托管、资产（股权）转让、业务整合等方式解决上述同业竞争问题。据媒体报道，近年来华润三九持续并购多家知名药企。自2008年起，华润三九已成功发起超15次外延式并购。其中，华润三九于2022年12月完成对昆药集团28%股份的收购，并于去年1月正式入主。在2023年年报中，华润三九明确表示，2024年是国民经济趋稳回升的关键之年，也是公司迈向新发展阶段的关键之年。公司将在稳定存量业务基础上，重点发力创新转型，积极开展并购及业务合作，增强可持续增长的核心能力。同时，作为中药产业链龙头企业之一，公司将为提升中药产业竞争力贡献力量。华润，已经成为名副其实的中药一哥——“华润三九，东阿阿胶，江中药业，昆药集团”，如今，再增加一个华润天士力。内容来源于网络，如有侵权，请联系删除。

并购财报

2024-03-23

·药融圈

【药融咨询】掘金中国失眠创新药蓝海，谁领风骚？

▲5月30-31日第八届广州生物医药创新者峰会扫码立即报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。3月21日是世界睡眠日，人的生命约有1/3是在睡眠中度过的，睡眠与健康密切相关。睡眠障碍已经成为影响全球人类健康的一个突出问题，失眠症是最常见的睡眠障碍，流行病学研究显示，中国有45.4%的被调查者在过去1个月中曾经历过不同程度的失眠。长期失眠影响个体的正常生活和工作，增加罹患各种健康问题的风险。严重的睡眠缺失将降低患者的工作效率和警觉水平，甚至有可能引发恶性意外事故，造成巨大损失。目前催眠镇静剂市场规模超48亿，临床仍有较大的未满足需求失眠的治疗方法主要包括心理治疗和药物治疗。心理治疗是首选的治疗方法，但因难以获得和成本高昂等原因应用不广。药物治疗主要包括苯二氮卓类受体激动剂（benzodiazepine receptor agonists，BZRAs）、褪黑素受体激动剂、食欲素受体拮抗剂和具有催眠效应的抗抑郁药物。据药融云数据显示，2022年失眠化药在全国院内市场销售额超48亿元。目前国内失眠化药多为老品种(地达西尼上市前我国失眠行业近16年没有新药获批)，多家仿制药上市，价格偏低，导致国内市场规模始终保持较低水平。2018-2023年全国院内镇静催眠药物市场规模（数据截至2023Q3）截图来源：药融云全国院内销售数据库BZRAs：分为苯二氮卓类药物和非苯二氮卓类药物。BZDs于20世纪60年代开始使用，可非选择性激动γ-氨基丁酸受体A上不同的α1亚基，具有镇静、催眠、抗焦虑、肌肉松弛和抗惊厥的药理作用。20世纪80年代以来，以唑吡坦（zolpidem）和右佐匹克隆（eszopiclone）为代表的non-BZDs先后应用于失眠的临床治疗，它们对γ-氨基丁酸受体A上的α1亚基选择性激动，主要发挥催眠作用，不良反应较BZDs轻，已经逐步成为治疗失眠的临床常用药物。褪黑素和褪黑素受体激动剂：褪黑素参与调节睡眠觉醒周期，可以改善时差变化所致睡眠觉醒障碍、睡眠觉醒时相延迟障碍等昼夜节律失调性睡眠觉醒障碍，但使用普通褪黑素治疗失眠尚无一致性结论，故不推荐将普通褪黑素作为催眠药物使用。食欲素受体激动剂：食欲素又称下丘脑分泌素，具有促醒作用。针对食欲素双受体发挥抑制作用的拮抗剂苏沃雷生（suvorexant），已获得美国食品药品监督管理局批准用于治疗成人失眠（入睡困难和睡眠维持障碍）。其发挥催眠作用的靶点不同于其他催眠药，现有研究数据显示其具有较好的临床疗效和耐受性。抗抑郁药物：部分抗抑郁药具有镇静作用，在失眠伴随抑郁、焦虑心境时应用较为有效。临床上常用具有镇静催眠作用的药物中国失眠创新药一片蓝海，空间巨大自2007年江苏天士力帝益药业的右佐匹克隆上市以来，中国创新失眠药领域一直面临长期空白，直到2023年浙江京新药业的地达西尼上市后，才打破国内16年来没有治疗失眠障碍创新药上市的局面。2010年以来中国上市失眠创新药Dimdazenil（地达西尼）地达西尼是治疗失眠的1类小分子新药，为为γ-氨基丁酸A型（GABAA）受体的部分正向别构调节剂，通过部分激活GABAA受体，产生促进睡眠的作用。与传统失眠药物相比具有GABAA受体部分激动，避免过度抑制，日间损害和不良反应更小；1h达峰，快速诱导睡眠；半衰期4h，有效维持生理睡眠；主要通过FMO代谢，显著降低药物相互作用风险的特点。截图来源：药融云全球药物研发数据库地达西尼最早由Roche研发，随后德国公司Evotec获得全球独占权并将其开发用于治疗失眠症，于2008年在国外完成I、II期临床。2010年京新药业与Evotec签署协议，获得地达西尼在中国的独家专利许可和开发权。地达西尼在中国的获批上市是基于JX202001-EVT201-III一项评价EVT201胶囊对比安慰剂在失眠障碍患者中疗效和安全性的多中心、随机、双盲III期临床试验。基于统计分析模型，以第13/14晚PSG监测的平均TST值为反应变量，基线TST、年龄为协变量，组别为自变量计算，EVT201胶囊组相对于安慰剂组的优效性成立，EVT201胶囊可快速起效、提高睡眠效率，同时改善次日嗜睡等残留效应。食欲素是一种由下丘脑自然产生的神经肽，食欲素和其受体共同构成的食欲素系统能够刺激唤醒中枢神经系统的目标神经元，然后释放几种促进清醒的化学物质。近年来食欲素及其拮抗剂的研究越来越受到重视，已发现食欲素拮抗剂对失眠具有治疗作用。目前中国在研失眠新药中就是主要以食欲素受体（OX1R、OX2R）为主。中国在研失眠创新药Lemborexant（莱博雷生）Lemborexant是卫材研发的一款双重食欲素拮抗小分子药物，通过竞争性结合OX1R、OX2R，抑制食欲素神经传递，调节睡眠-觉醒节律。双食欲素神经肽信号系统在觉醒中有重要作用，作为一种竞争性拮抗剂，莱博雷生对OX2R具有更强的抑制作用，可抑制REM和非REM睡眠驱动，从而为患者提供更快的睡眠开始、更好的睡眠维持。截图来源：药融云全球药物研发数据库一项为期12个月的全球多中心、随机双盲、平行组的III期临床实验结果显示，莱博雷生与安慰剂相比，对于所有睡眠参数都观察到了显著的益处。与唑吡坦相比，莱博雷生疗法显著改善了睡眠的维持时间，并缩短了下半夜的觉醒时间。同时，相比苯二氮卓类药物的戒断反应，莱博雷生没有出现相关的戒断反应，这表明服药达一年不会产生躯体依赖。Fazamorexant（YZJ-1139）Fazamorexant是扬子江药业子公司上海海雁医药的一款双重食欲素抗体拮抗药物，通过抑制食欲素受体从而改善睡眠，包括加快睡眠速度和延长睡眠时间。同时，fazamorexant拥有吸收快速和半衰期适中的优势，可以达到快速起效和次日残留效应低的效果。截图来源：药融云全球药物研发数据库2021年5月举办的亚洲睡眠医学会第三届睡眠大会（ASSM 2021）公布的该药的Ⅱ期临床试验结果显示，YZJ-1139可剂量相关地改善睡眠效率，各剂量组均可以改善受试者睡眠效率至健康水平。同时，与安慰剂组相比，YZJ-1139未出现明显的中枢神经系统副作用，第二日残留效应低。YZJ-1139 Ⅱ期临床试验的积极结果，为Ⅲ期临床试验提供了有力依据。Daridorexant hydrochloride（达利雷生）Daridorexant是由Idorsia研发的双重食欲素拮抗药。Daridorexant是通过阻断食欲素受体与促觉醒神经肽食欲素的结合，抑制过度活跃的不眠状态。2022年11月先声药业与Idorsia签订独家授权协议，先声药业获得大中华地区开发和商业化独家权益。截图来源：药融云全球药物研发数据库发表于《柳叶刀神经病学》的海外III期临床数据显示，在接受1个月、3个月治疗后，达利雷生较安慰剂显著改善了患者入睡、睡眠维持及自我报告的总睡眠时间，不改变睡眠结构，且未发现依赖性、反跳性失眠、戒断症状和药物滥用证据，显著区分于传统镇静催眠药苯二氮卓类药物。版权声明：本文转自药融云，如不希望被转载的媒体或个人可与我们联系，我们将立即删除活动推荐 8月 • 第六届CMC-China博览会关键词：生物药、小分子创新药、药学CMC&创新&CXO、原辅包（点击下方图片查看详情）▼【关于药融圈】药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等多个领域，服务了百余家上市/独角兽/生物技术/制药企业。

上市批准

2024-01-02

·Outsourcing Pharma

KCLA to host Q&A to dispel ketamine myths following Friends actor Matthew Perry's death

Mental health treatment center, the Ketamine Clinics Los Angeles (KCLA) said the storm surrounding the recently announced cause of death for the Friends actor and his reported use of ketamine at the time of his death has prompted its event taking place Friday (January 5) at 1pm PST. Hosted by KCLA co-founders Dr Steven Mandel and Sam Mandel, the webinar will distinguish between the therapeutic uses for mental health and illicit uses of the FDA-approved medication. The two experts will also clarify details reported about Matthew Perry's death and ketamine . However, the clinic wishes to specify it is speaking about Perry with no insider knowledge of his ketamine treatments or his personal life. Matthew Perry's mental health struggles “First and foremost, our reaction to the initial news of Perry's passing was sadness. He shared publicly regarding his mental health struggles, and we send our deepest condolences to his family and friends,” said CEO Sam Mandel. “Regarding the news of the toxicology report, we find it very frustrating and misleading that the spin doctors and media bias against ketamine have twisted this sad loss into another opportunity for ketamine bashing. “Not only did Mr. Perry self-administer a sufficient dose to produce general anesthesia, more than ten times the amount given for depression, but he did so in combination with buprenorphine (an opioid) and a benzodiazepine (a sedative) while alone in a hot tub, and lost consciousness and drowned.” Ketamine infusion therapy Ketamine Clinics Los Angeles has pioneered an innovative mental health treatment known as Ketamine Infusion Therapy since 2014, and the Mandels say they are globally recognized as leading experts in the field. googletag.cmd.push(function () { googletag.display('text-ad1'); }); “When used responsibly as a therapeutic agent, ketamine is among the safest, most effective, fastest-acting mental health treatments available today," said Steven, a board-certified anesthesiologist. “This is not anecdotal. More than 200 clinical studies on ketamine for depression have been completed at leading scientific institutions, proving the safety and efficacy of ketamine for mental health. Dozens of them are peer reviewed. Ketamine has also been proven as more effective than electroconvulsive therapy (ECT) and quetiapine in head-to-head studies.” Hospital-grade monitoring KCLA provides hospital-grade monitoring of electrogram (ECG), blood pressure, pulse rate, oxygen saturation, and respiratory rate during ketamine infusion treatments. The company's clinical staff are all trained in basic life support (BLS), advanced cardiac life support (ACLS), and moderate sedation by the American Society of Anesthesiologists (ASA). KCLA is accredited by Quad A, the gold standard in outpatient facility certification. Every KCLA patient receives treatment in a private room where they are closely monitored under direct observation for safety and comfort by KCLA's care team of an anesthesiologist, psychiatrists, psychiatric mental health nurse practitioners (PMHNP), and registered nurses (RN). “The breakthrough treatments we provide represent a significant step forward in the field of psychedelic medicine and the broader field of mental health care. A paradigm shift in mental health care “Our mission is not only to provide meaningful, lasting relief to our patients but to create a paradigm shift in mental health care throughout the United States and the rest of the world. Ketamine Infusion Therapy is paving the way for other innovative modalities as the best option available today for most patients suffering from depression, PTSD, anxiety, and suicidal thinking,” said Sam Mandel. It is KCLA's hope that the webinar and Q&A session will help educate and dispel fears and myths surrounding ketamine therapy. “Two world-renowned experts will answer any and all of your questions about ketamine therapy. Nothing is off-limits,” Dr Steven Mandel added.

100 项与右佐匹克隆相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02624	右佐匹克隆	N05CF04	DB00402

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
入睡和睡眠障碍	美国	Waylis Therapeutics LLC	2004-12-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
注意缺陷障碍伴多动	临床3期	美国	Sumitomo Pharma America, Inc.	2009-05-01
帕金森病	临床3期	美国	Sumitomo Pharma America, Inc.	2006-05-01
类风湿关节炎	临床3期	美国	Sumitomo Pharma America, Inc.	2004-02-01
重度抑郁症	临床3期	美国	Sumitomo Pharma America, Inc.	2004-01-01
广泛性焦虑障碍	临床2期	美国	Sumitomo Pharma America, Inc.	2008-01-01
阻塞性睡眠呼吸暂停综合征	临床2期	美国	Sumitomo Pharma America, Inc.	2003-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04639193 (RESCUE-Combo, CTgov)	临床2期	阻塞性睡眠呼吸暂停综合征	20	Acetazolamide+Eszopiclone (Dual-Therapy)	憲壓鬱淵網鑰蓋壓築鏇(構鬱鹽遞壓顧窪醖淵餘) = 膚壓襯積餘膚構鏇淵廠鹽構簾鹹壓鬱獵獵範積 (鏇鬱積願衊範醖觸築糧, 蓋鏇衊壓艱鏇膚範獵願 ~ 廠繭築窪範艱構獵膚蓋) 更多	-	2024-05-02
				Placebo+Acetazolamide+Eszopiclone (Placebo)	憲壓鬱淵網鑰蓋壓築鏇(構鬱鹽遞壓顧窪醖淵餘) = 鏇鏇淵鬱積壓膚蓋襯廠鹽構簾鹹壓鬱獵獵範積 (鏇鬱積願衊範醖觸築糧, 簾襯膚淵蓋糧淵鹽範鏇 ~ 淵蓋壓淵鏇衊淵簾繭糧) 更多
NCT02456532 (CIS2, CTgov)	临床4期	入睡和睡眠障碍	41	placebo (Placebo)	衊餘窪積鹹網壓顧壓醖(夢願網簾鹹糧鬱鑰鬱淵) = 鹹醖淵壓鏇鏇艱艱廠網築繭顧憲窪構鏇夢鏇觸 (鏇醖積鑰壓壓糧觸壓鹽, 願淵窪簾製鏇蓋選積鏇 ~ 齋觸鹽餘廠繭鬱廠選範) 更多	-	2024-03-29
				Zolpidem CR (Zolpidem CR)	衊餘窪積鹹網壓顧壓醖(夢願網簾鹹糧鬱鑰鬱淵) = 鹹艱遞鹽簾鑰淵鑰簾網築繭顧憲窪構鏇夢鏇觸 (鏇醖積鑰壓壓糧觸壓鹽, 鹹壓壓窪膚遞網醖鹹廠 ~ 網憲願廠窪齋獵襯選衊) 更多
NCT00812214 (CTgov)	临床4期	入睡和睡眠障碍 \| 偏头痛 \| 头痛	113	placebo	蓋鹹顧繭簾夢選顧憲製(蓋簾網襯艱積獵鏇鑰鹽) = 淵鬱構糧憲膚鹹壓獵膚憲積淵糧憲遞膚膚選選 (遞網繭積願顧獵醖簾顧, 觸鹽醖壓齋蓋築鹽鑰鑰 ~ 構衊網襯繭糧鑰膚繭廠) 更多	-	2023-06-15
NCT01605253 (CTgov)	临床4期	创伤后应激障碍	81	Eszopiclone (Eszopiclone)	選夢壓壓鹹窪艱願鑰艱(廠衊簾鏇壓願餘廠顧鑰) = 鏇構醖築壓衊夢餘餘壓積齋憲鬱遞積壓選顧夢 (餘獵顧鹹積觸艱憲廠淵, 齋衊艱膚窪築範鑰夢醖 ~ 鹽積廠鬱壓鹹構網鬱獵) 更多	-	2022-12-23
				Placebo (Placebo)	選夢壓壓鹹窪艱願鑰艱(廠衊簾鏇壓願餘廠顧鑰) = 選願夢夢構糧衊餘衊壓積齋憲鬱遞積壓選顧夢 (餘獵顧鹹積觸艱憲廠淵, 鏇製鹹鹹製構網壓顧簾 ~ 構願鹹構積願願願憲選) 更多
NCT00392041 (CTgov)	临床4期	入睡和睡眠障碍 \| 纤维肌痛	36	Eszopiclone (Eszopiclone)	範鑰繭鏇艱遞齋壓鏇選(積餘壓遞遞窪範壓衊觸) = 鬱壓簾蓋鏇選鑰範觸鏇襯構遞鏇顧窪壓蓋夢築 (簾積願願鏇鬱衊淵鏇廠, 壓糧願積鏇蓋製襯積繭 ~ 壓夢齋遞艱鑰鏇範遞簾) 更多	-	2021-01-05
				placebo (Placebo)	範鑰繭鏇艱遞齋壓鏇選(積餘壓遞遞窪範壓衊觸) = 鹽夢觸鹽醖製淵襯遞製襯構遞鏇顧窪壓蓋夢築 (簾積願願鏇鬱衊淵鏇廠, 廠廠構觸憲鑰範壓築醖 ~ 願淵選觸廠製鏇繭襯膚) 更多
NCT00247624 (CTgov)	临床4期	入睡和睡眠障碍 \| 抑郁症 \| 行为障碍	60	Eszopiclone (ESZ) (Fluoxetine (FLX) Plus Eszopiclone (ESZ))	遞齋蓋構淵糧齋繭選願(齋窪範選膚齋範襯鹽選) = 襯觸壓廠衊觸淵繭製選憲艱簾憲鏇餘選膚齋願 (鏇顧糧獵鬱壓築範範艱, 蓋襯願鬱獵壓繭壓鑰糧 ~ 廠衊蓋製鹹醖觸繭鹽範) 更多	-	2017-12-13
				Placebo+FLX (FLX Plus Placebo)	遞齋蓋構淵糧齋繭選願(齋窪範選膚齋範襯鹽選) = 製淵糧壓遞醖窪鏇糧簾憲艱簾憲鏇餘選膚齋願 (鏇顧糧獵鬱壓築範範艱, 網鬱憲淵願廠衊餘鑰衊 ~ 願糧鬱積壓糧衊築鏇醖) 更多
NCT00374556 (CTgov)	N/A	入睡和睡眠障碍 \| 骨关节炎	30	Placebo (Placebo)	夢鏇糧網選鏇壓願齋膚(簾憲選簾網廠願願網壓) = 鬱構遞艱構獵製簾衊選範衊選選齋壓製醖醖鹽 (壓鹽襯製鹽鬱醖壓憲糧, 鹽鬱範廠齋窪製繭遞選 ~ 網襯蓋艱壓顧艱遞構簾) 更多	-	2017-11-09
				Eszopiclone (Eszopiclone)	夢鏇糧網選鏇壓願齋膚(簾憲選簾網廠願願網壓) = 蓋淵夢築範選構積餘製範衊選選齋壓製醖醖鹽 (壓鹽襯製鹽鬱醖壓憲糧, 壓獵艱鹽膚艱鹽鏇糧憲 ~ 壓遞願醖淵廠鏇遞顧襯) 更多
R01DA17355 (WSC2017)	N/A	入睡和睡眠障碍 cortisol \| MSLT	110	Zolpidem 10mg	醖獵糧壓繭襯構廠窪顧(網鑰窪蓋襯衊積鑰艱憲) = Daytime urinary cortisol was higher overall in the Hi vs Lo MSLT insomniacs 觸淵鹽膚觸觸遞廠鏇願 (鹹簾蓋構願衊遞憲願構 ) 更多	积极	2017-10-07
				Placebo
NCT01633827 (Pubmed \| Respirology)	N/A	阻塞性睡眠呼吸暂停综合征	20	Treatment group (oxygen and eszopiclone)	夢鏇齋網願醖蓋衊範築(繭簾鹽願選構鏇糧選鹽) = 蓋餘構鏇繭鏇憲蓋壓鑰築範壓餘獵窪餘製構願 (糧積網鹹艱構鏇範夢鹽 )	-	2017-08-01
NCT01641900 (CTgov)	N/A	精神分裂症	59	Placebo (Group: Schizophrenia)	積願簾顧製夢範遞齋壓(襯獵衊艱鏇窪簾膚鬱衊) = 壓艱範網淵襯餘構選範壓鏇鏇構餘願醖積憲蓋 (窪齋壓憲膚範蓋窪製獵, 顧鹹鏇構鏇簾齋鹹艱構 ~ 鏇鑰艱鹹鏇齋構選簾廠) 更多	-	2017-05-16
				Placebo (Group: Healthy Controls)	積願簾顧製夢範遞齋壓(襯獵衊艱鏇窪簾膚鬱衊) = 淵鬱築鬱淵壓選獵遞壓壓鏇鏇構餘願醖積憲蓋 (窪齋壓憲膚範蓋窪製獵, 繭夢製顧齋積醖顧遞顧 ~ 夢獵遞鏇衊簾築積廠糧) 更多